




**Oncode
Institute**

*Outsmarting cancer
Impacting lives*

Therapieontwikkeling van morgen

GGG congres - ZonMw

April 6, 2017
Anton Berns

Funded
by



Oncode Institute is an independent organization dedicated to understanding cancer and translating new insights into effective therapies at sustainable prices.

Official Funders



Partner Institutions



Founding Scientists



Hans Bos



René Bernards



Jan Hoeijmakers



Hans Clevers



Anton Berns



Research Groups

Oncode Institute Model

- **Virtual Research Institute**
- **Common Research Strategy**
- **Private and Public Funding**
- **Single Valorization Team**
- **€24MM per year for 5 years**
- **43 growing to 55 PI's including dedicated funding for young female investigators**
- **Performance metrics based on science, collaboration and valorization**
- **Base funding to each PI**
 - €150k - €250k per year
- **Additional funds**
 - Equipment and Infrastructure
 - Technology Access
 - Clinical Proof-of-concept
 - Institute Initiatives
- **Programs**
 - Technology access
 - Young female investigators
 - Training program – aimed at all levels

Hoe houden wij de kosten van de kankergeneesmiddelen in de hand?

	PER TREATMENT	PER YEAR
PEMBROLUZIMAB (KEYTRUDA®)	€ 5.512	€ 95.541
IPIILIMUMAB (YERVOY®)	€ 21.000	€ 84.000
NIVOLUMAB (OPDIVO®)	€ 2.914	€ 75.764
COMBI IPIILIMUMAB-NIVOLUMAB	€ 27.000	€ 166.200



Hoe houden wij de kosten van de kankergeneesmiddelen in de hand?

	PER DAY	PER YEAR
IMATINIB (GLIVEC®)	€ 138	€ 50.370
OSIMERTINIB (TAGRISSO®)	€ 406	€ 148.000
COMBI DABRAFENIB-TRAMETINIB	€ 508	€ 184.000



What is the use of innovation if nobody can afford the result of it?



Two categories of drugs could be brought to the clinic relatively quickly and cheaply

- **Drugs that were abandoned during clinical development due to lack of single agent activity**
- **Patent expired drugs for which new indications are found**
- **through research**

Patent expired drugs are cheaper

			PER YEAR	PATENT EXPIRATION
		IMATINIB- CML - 600MG/DAY	€ 1.861	2016
		IMATINIB- GIST - 600MG/DAY	€ 50.370	2021



An example of finding a new indication for an old drug:



NKI research



ClinicalTrials.gov

A service of the U.S. National Institutes of Health

[Find Studies](#) [About Clinical Studies](#) [Submit Studies](#) [Resources](#) [About This Site](#)

[Home](#) > [Find Studies](#) > [Search Results](#) > [Study Record Detail](#)

Trial record 1 of 1 for: NCT02838548

[Previous Study](#) | [Return to List](#) | [Next Study](#)

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

This study is currently recruiting participants. (see [Contacts and Locations](#))

Verified July 2016 by The Netherlands Cancer Institute

Sponsor:
The Netherlands Cancer Institute

Information provided by (Responsible Party):
The Netherlands Cancer Institute

ClinicalTrials.gov Identifier:
NCT02838548

First received: June 24, 2016

Last updated: July 18, 2016

Last verified: July 2016

[History of Changes](#)

Compound patent
Expired 2015
Cost: \$110,000/year
Cutaneous T cell lymphoma



Jan Schellens
Medical Oncologist
Principal Investigator



Jos Beijnen
Pharmacist
Drug manufacture &
pharmacology

Drug made by NKI pharmacy
trial sponsored by charity and EU
Drug cost EUR 1500 per year



Thank you

Principal funder



Funders



Ministerie van Onderwijs, Cultuur en
Wetenschap



Ministerie van Economische Zaken



Ministerie van Volksgezondheid,
Welzijn en Sport

Health~Holland
SHARED CHALLENGES, SMART SOLUTIONS